{"entity":{"id":"nct05727176","kind":"trial","name":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","aka":[],"tldr":"A phase 2 trial of TAS-120 in biliary tract cancer, run by Taiho Oncology, Inc., now recruiting.","summary":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT05727176 by Taiho Oncology, Inc., with 120 participants planned, started 2023-07-05 and due to reach its primary completion in 2026-12. Interventions recorded: TAS-120.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05727176","url":"https://clinicaltrials.gov/study/NCT05727176"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05727176","phase":"2","setting":"Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements","sponsor":"Taiho Oncology, Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct05727176/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"company":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/"}]}}